Short Interest in PureTech Health plc (NASDAQ:PRTC) Declines By 22.1%

PureTech Health plc (NASDAQ:PRTC - Get Free Report) saw a significant drop in short interest in May. As of May 15th, there was short interest totalling 8,100 shares, a drop of 22.1% from the April 30th total of 10,400 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 5,200 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Trading of PureTech Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRTC. Birch Hill Investment Advisors LLC acquired a new position in shares of PureTech Health in the fourth quarter worth about $5,575,000. Millennium Management LLC purchased a new position in shares of PureTech Health in the 4th quarter valued at about $823,000. Finally, Pentwater Capital Management LP raised its holdings in PureTech Health by 39.2% in the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock worth $664,000 after purchasing an additional 9,449 shares during the period. Institutional investors and hedge funds own 0.04% of the company's stock.

PureTech Health Trading Up 0.4%

PureTech Health stock traded up $0.08 during mid-day trading on Friday, hitting $18.88. The company had a trading volume of 1,133 shares, compared to its average volume of 4,670. PureTech Health has a 12-month low of $13.30 and a 12-month high of $29.80. The company's fifty day moving average is $17.23 and its 200-day moving average is $18.54.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.